Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 6/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 3/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3104908 | 0.90 | PPARD (0.46) | PPARDSRD5A2MRGPRX4RXRANR1H2 | |
| SCHEMBL3106760 | 0.86 | SPHK2 (0.46) | PPARDPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL3101002 | 0.85 | PPARD (0.43) | PPARDSRD5A2RXRANR1H2NR1H3 | |
| SCHEMBL3906291 | 0.81 | PPARD (0.59) | PPARDPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL3101970 | 0.79 | PPARD (0.46) | PPARDSRD5A2NR4A2MRGPRX4RXRA | |
| SCHEMBL3101111 | 0.79 | PPARD (0.48) | PPARDSRD5A2NR4A2MRGPRX4RXRA | |
| SCHEMBL3102399 | 0.78 | PPARD (0.43) | PPARDSRD5A2NR4A2RXRAPPARG | |
| SCHEMBL3101927 | 0.78 | GCGR (0.49) | PTGER4 | |
| SCHEMBL3907312 | 0.78 | PPARA (0.43) | PPARDRXRANR1H2NR1H3PPARG | |
| SCHEMBL13791244 | 0.77 | PPARA (0.48) | PPARDRXRANR1H2NR1H3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210876-B1 | HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST | TAKEDA PHARMACEUTICAL (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-8309580-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2210876-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256156-A1 | HETEROCYCLIC COMPOUND | GLP1R, GPR119, GCGR | PPARD 1129/4885SRD5A2 607/4885NR4A2 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.